enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 4,800 shares, a growth of 4,700.0% from the March 15th total of 100 shares. Based on an average daily trading volume, of 10,400 shares, the short-interest ratio is presently 0.5 days.

enGene Stock Performance

Shares of enGene stock opened at $0.67 on Wednesday. The stock’s 50-day simple moving average is $0.72 and its 200-day simple moving average is $1.12. enGene has a 52 week low of $0.42 and a 52 week high of $4.70.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.